Oral anticoagulant therapy for venous thromboembolism (VTE) is very effective. When oral anticoagulants are managed well, the risk of recurrence is approximately 2 per 100 patientyears. The main reasons for a breakthrough event can be split into underlying disease and subtherapeutic drug levels. The most common underlying disease that results in recurrence on treatment is cancer. Subtherapeutic drug levels can be caused by poor adherence to the drug regimen, interactions with other drugs or food, or inappropriate dosing. It is important to investigate and understand the cause whenever such an event occurs, in order to provide improved anticoagulant management, thereby avoiding further recurrences. Four illustrative cases will be presented here together with a discussion around the underlying pathology.
Introduction
baseline ultrasonography of both legs and computed tomography (CT) or ventilation-perfusion scanning of the lungs, whether they had symptoms or not. Central adjudication of locally suspected recurrences on diagnostic imaging, using comparisons with baseline did not confirm suspected recurrent pulmonary embolism in 7.5% and did not confirm suspected recurrent deep vein thrombosis in 11.8% (unpublished data). Especially ipsilateral recurrence of thrombosis poses a diagnostic challenge. When there is questionable difference in extension of the VTE between the images from the first event and the recurrence a negative D-dimer in a patient with onset of symptoms within the last few days speaks against a true recurrence.
Patients admitted to hospital with new diagnosis of pulmonary embolism while already on warfarin have, compared to those admitted with pulmonary embolism not on anticoagulation, after discharge from the hospital a 4.4-fold higher risk of fatal recurrent pulmonary embolism. 8 These deaths are mainly related to cardiovascular disease, malignancy and sepsis.
Causes for breakthrough thromboembolism
Underlying condition or disease. There are many potential causes for recurrence of VTE despite anticoagulant therapy. From the above-mentioned trial data it is obvious that presence of cancer increases the risk of recurrence. In the largest registry of VTE treatment in clinical practice, Registro Informatizado de la Enfermedad Trombo Embolica (RIETE), every third patient with recurrence on VKA therapy had cancer. 9 This is the cardinal example of an underlying disease exhibiting pronounced thrombogenicity that overcomes the protective effect of anticoagulants. The malignant tumors exert this effect through several mechanisms that among others involve activation of coagulation and obstruction of blood flow, extensively reviewed elsewhere. 10 For patients with myeloproliferative neoplasms (polycythemia vera and essential thrombocythemia) molecular profiling with analysis of JAK2, CALR and MPL mutations can add information on the risk of thrombosis that often occurs in atypical sites. 11 Diseases or conditions with an increased risk of recurrent VTE on anticoagulation are summarized in Table   For personal use only. on . by guest www.bloodjournal.org From 1. The mechanism behind the increased thrombogenicity is sometimes unclear, such as in Behçet's disease and antiphospholipid syndrome and many alternatives have been proposed (Table 1) . For heparin-induced thrombocytopenia the pathogenesis has, however, been explained -IgG antibodies recognizing the multimolecular complexes between heparin and platelet factor 4 assemble on the surface of platelets that become activated and release procoagulant microparticles. 12 A minority of patients with antiphospholipid syndrome display a falsely elevated international normalized ratio (INR), possibly due to antibodies against tissue factor, and they may thus have recurrent events despite "optimal" INRs. 13 They would typically have demonstrated a prolonged prothrombin time before starting on an anticoagulant and alternative thromboplastins that are insensitive to the lupus anticoagulant should then be used for monitoring warfarin therapy. 14 
INR
results from point-of-care instruments are variable and not reliable for patients with lupus anticoagulant.
Paroxysmal nocturnal hemoglobinuria, diagnosed in 1/100,000/year, 15 caused by the expansion of an abnormal hematopoietic clone, is characterized by intravascular hemolysis, cytopenias and thrombosis. The latter often occur in unusual sites (intraabdominal or intracranial veins) and treatment failures on anticoagulant therapy have been reported at 10.6 events per 100 patientyears. 16 In one study 9 of 41 patients with thrombosis experienced recurrences on anticoagulants. 17 A concomitant bleeding tendency makes it often difficult to increase the anticoagulant intensity and targeting of the terminal complement activation complex by addition of eculizumab is probably the best solution.
18,19
During pregnancy many changes occur in the prohemostatic direction, essentially preparing the woman for childbirth without massive bleeding but with a concomitant increase in risk of thrombosis (Table 1) . Furthermore, presence of the antiphospholipid syndrome will increase the risk of gestational venous thromboembolism as well as unexplained fetal death, spontaneous Finally, vascular anomalies with chronic obstruction of the venous flow may cause recurrences while on anticoagulation, typically in young patients. These abnormalities include the thoracic outlet syndrome and May-Thurner syndrome (compression of the left common iliac vein by the right iliac artery). 24 Several options for the management of these thrombotic events exist, including initial thrombolysis, pharmaco-mechanical clot removal, endovascular stenting or decompressive surgery (thoracic outlet syndrome).
25
Inappropriate dosing of anticoagulant. For patients treated with VKA it is crucial to remember that it takes at least 5 days for all the vitamin K dependent coagulation factors to decrease to sufficiently low activity in order to provide a therapeutic anticoagulant effect.
Therefore, overlap with a parenteral anticoagulant for at least 5 days and until the INR has reached 2.0 for at least 24 h is recommended (Grade 1B -explained in Table 2 ). Another scenario with suboptimal exposure is the morbidly obese patient. There are no recommendations for dose adjustments of NOACs for this population that was underrepresented in the clinical trials.
Patients with major gastrointestinal tract surgery might have reduced absorption of a NOAC. In a review of the literature only case series or single case reports were identified. 35 It appeared that reduced anticoagulant efficacy could be experienced with dabigatran, and possibly also with rivaroxaban after Roux-en-Y gastric by-pass or after gastrectomy. There was no information regarding the absorption of apixaban or edoxaban in such cases.
In the setting of stroke prophylaxis in atrial fibrillation it has been shown that patients are more stroke averse than physicians but physicians are more bleeding averse than patients, leading to underdosing. 36 The NOACs are typically labelled for a standard dose and a reduced dose
For personal use only. on . by guest www.bloodjournal.org From regimen according to specific criteria for the indication stroke prophylaxis in atrial fibrillation and in some countries also for VTE. Retrospective chart reviews have shown a high degree of inappropriate dose selection even in hospitals, 37, 38 with many of those patients receiving a suboptimal dose. This may be true also for the patients with VTE and thus another explanation for breakthrough events. The approved dose regimens for treatment of VTE with NOACs differ somewhat between the United States and other countries. For example, dabigatran is only approved at a dose of 150 mg twice daily in the United States whereas other countries have in the label a dose reduction to 110 mg twice daily for patients over 80 years of age or over 75 years of age in combination with increased risk of bleeding. This dose reduction is not based on data from the studies on treatment in VTE and only observational studies will confirm if this dose is sufficiently effective. 39 There are also criteria based on low body weight, impaired renal function, and/or old age for reduction of the dose of rivaroxaban or apixaban in patients with atrial fibrillation but not in patients with VTE, which is bound to result in confusion. Conversely, for edoxaban, the dose reduction is recommended for both indications for patients with moderate renal impairment, low body weight and/or concomitant use of P-gp inhibitors (Table   3 ).
Evaluation and Investigation of the patient
A suggested algorithm for evaluation of the cause for recurrent VTE on anticoagulation is shown in 
Initial investigation and anticoagulation
We suspect a malignancy and order a CT of the abdomen and pelvis. In the SOMIT study this was the investigation with the highest yield in the group allocated to extensive screening for cancer. 40 While awaiting the CT result we stop warfarin and start LMWH at a therapeutic dose.
The CT demonstrates pancreas cancer with liver metastases. Therefore, the patient will continue on LMWH at a therapeutic dose rather than going back to an oral anticoagulant for now. This is in accordance with the recommendations by guidelines from the American College Beyond the acute phase
The CLOT study used a protocol with the LMWH dalteparin at full therapeutic dose for 1 month, followed by 75% of the dose for the next 2-5 months. 46 In the CATCH study patients in the LMWH arm received tinzaparin at full therapeutic dose for the entire 6 months. 47 The guideline and guidance documents do not express any suggestion regarding dose reduction after a certain number of months. 41, 42, 44 This has left me in my practice with a choice to maintain the dose at 100% or reduce to 75% after 1 month depending on the perceived risk of recurrence (thrombogenic tumor type, extensive thromboembolism) and risk of bleeding.
For patients with a calculated creatinine clearance below 30 mL/min, corresponding to severe renal impairment, the dose of enoxaparin should be reduced to 1 mg/kg once daily. The product monographs for dalteparin and tinzaparin recommend that for patients with severe renal impairment a dose reduction should be considered without specifying by how much. Nadroparin is contraindicated in severe renal impairment.
Recurrent venous thromboembolism on therapeutic dose LMWH
In a retrospective study of patients with cancer and with recurrent VTE on anticoagulation, 47
patients that already were receiving treatment with therapeutic dose LMWH had dose escalation of 20-25% for 4 weeks. 48 Some patients were on a prophylactic dose and others on a therapeutic dose LMWH when the breakthrough event happened. Only the latter subset were 45 The ACCP guidelines recommend a dose escalation of LMWH by "one-quarter to one-third" (Grade 2C) 41 and ASCO recommends a 20-25% increase (no grade).
44
In clinical practice it is often difficult to maintain patients on a twice-daily injection regimen for prolonged periods. After a recurrence on enoxaparin at 1.5 mg/kg daily one can change to either enoxaparin 1 mg/kg twice daily, or for patients that are not overweight to tinzaparin at slightly more than 200 units/kg once daily, which still might fit into one prefilled syringe.
Insertion of vena cava filter is not recommended for these patients unless there is a contraindication to anticoagulation or if there is recurrent pulmonary embolism on adequate anticoagulation. 42 The NOACs are not yet recommended for the initial treatment in the absence of any study comparing such a drug head-to-head with LMWH. In the near future results are expected from such a study comparing edoxaban with LMWH 49 , and another study comparing apixaban with LMWH (NCT03045406). After the first 3-6 months of treatment patients that still have active cancer continue to have a high risk of recurrent VTE. It is unlikely that we will see a study comparing different anticoagulants for this extended phase. 50 Here, NOACs are a valid option in view of the data from a meta-analysis of subgroups from the phase III trials with NOACs, 4 but VKA or, for patients that still tolerate it, LMWH are other options. Treatment suggestions for recurrent VTE in patients with cancer on anticoagulation are summarized in Fig. 2 . Decisions on dose reductions should take into account the bleeding risk and renal function.
For 51 Ventilation-perfusion lung scanning demonstrates bilateral segmental defects on the perfusion but not on the ventilation scan, thus high probability for pulmonary embolism.
Treatment should now be switched back to LMWH at a therapeutic dose for 1 week. Once the symptoms have abated, the dose can be reduced to a prophylactic level, for example dalteparin 5000-7500 IU daily or enoxaparin 40-60 mg daily. In a systematic review, long-term anticoagulation with LMWH was similarly effective and had a lower risk of bleeding than VKA.
52
Although several of the 15 included studies had used a therapeutic dose LMWH also in the long term, there are similar results for efficacy after pooling the 6 studies with a prophylactic doseodds ratio for recurrent VTE 0.91 (95% CI, 0.50-1.60) for LMWH versus VKA. In a case series with 24 patients with antiphospholipid syndrome and thrombosis, long-term secondary prophylaxis was given with dalteparin, 5000 units daily for a mean of 309 days with only one failure reported. 53 For patients like the one in this example with a recurrence on VKA I would give the higher prophylactic dose, e.g. dalteparin 7500 IU or enoxaparin 60 mg daily long-term.
One of the NOACs could be a more convenient alternative for this patient once she stops breast-feeding, and there are emerging data from case series 54 and subgroup analyses from good appetite and normal bowel function. 5 years ago, in his home country, he had some kind of inflammation in one eye. Upon further questioning, he admits to having had some ulcers in his mouth that he thought were "cold sores". On physical examination there are no current mouth sores or genital sores but there is acne. The visual acuity is decreased on the eye where he had the inflammation.
Behçet's disease is suspected since the patient appears to fulfil the obligatory criterion of mouth sores and 2 of the additional 4 signs required (possible uveitis and acne but not genital sores and no pathergy test yet). The pathology of venous thrombosis in Behçet's disease is mainly attributed to inflammation of the vessel wall and the thrombi become very adherent with a low risk for pulmonary embolism. 58 Anticoagulants have not provided good protection against recurrences in reported cases. 59 In the recommendations of the European League Against Instead, immunosuppressive agents are recommended ( The patient has not had any weight loss, and review of systems is negative. He works as a taxi driver. The patient claims that he is taking rivaroxaban diligently once daily and his pharmacy verifies that he renewed his prescription on the expected date. However, he admits that he does not always have time to eat breakfast in the morning when he takes his medication. We have thus a patient that appears compliant but has a body weight at the extreme of the population in the clinical trials (14% weighed >100 kg) and the absorption of the drug has been suboptimal part of the time. Pharmacokinetic results from human volunteers showed that the peak concentration of rivaroxaban (C max ) was unaffected in subjects >120 kg, 63 but only 12 subjects had a body weight >100 kg. A guidance document from ISTH on the use of NOACs for obese patients suggests that these drugs should not be used for a body weight >120 kg. 64 It also suggests that if a NOAC anyhow is used, drug-specific levels at peak and trough should be obtained. Pharmacokinetic studies in healthy subjects also showed that the absorption of the 20
For personal use only. on . by guest www.bloodjournal.org From mg dose of rivaroxaban taken on a fasting stomach is 66% of the absorption when taken with food 33 and in patients the difference might be greater. 34 We obtained a rivaroxaban-calibrated drug level 3 hours after the patient took a dose with food and it was 55 ng/mL, which is quite low. Thus, it is reasonable to follow the ISTH guidance document 64 and abandon further treatment with a NOAC and continue instead with warfarin, overlapping initially with LMWH. 
Conclusion

